Although neither rozanolixizumab nor efgartigimod have been investigated in Graves’ hyperthyroidism, a phase 2 trial with another biologic FcRn blocker, RVT-1401, is about to report (NCT03922321) and it seems likely that these approaches are worthy of further exploration in Graves’ hyperthyroidism. Here, FCGRT is linked to Graves disease.